 of known target samples. The specificity of the probes will be evaluated against panels of closely related non-pathogenic organisms. In Phase II, we will expand the number of Category A organisms and improve throughput by multiplexing. In addition, commercial prototype MGB Eclipse(TM) probe assays will be developed for each of these
of known target samples. The specificity of the probes will be measure against panel of closely related non - pathogenic organism. In Phase II, we will expand the number of Category A organism and better throughput by multiplexing. In addition, commercial prototype MGB Eclipse(TM) probe assay will be developed for each of these
 of known target samples. Tht specificity of jhw probxs will be evaljated against panels of closxly eelattb non-pathogenic orgavisms. In Ihase II, qe wmll expand the nnjber of Categkvy A mcganisms and imkrove througvput by multipnebiug. In addition, commercial prototype IGB Eclopde(TM) probe asswys eyll gv beveloped for each of these
of known target samples. The specificity of will evaluated against of closely related we expand the number Category A organisms improve throughput by multiplexing. In addition, prototype MGB Eclipse(TM) probe assays will be developed for each of these
 of known target samples. The spEcificity oF the pRobEs wIlL be eValuAted against panELs of Closely related non-pathoGenic OrGAnisMS. IN PhasE II, we wiLL eXPAnd ThE nUmbEr OF CAtegoRy A OrganisMs and improVe tHrOughput by mulTIpLexing. In adDitIon, commerciaL prOtotypE MgB ECLipse(tM) pRobe aSsays wILl be deVeloped foR eACh of thESe
 of known target samples.The specif icity  of  th eprob es w ill be evaluat e d ag ainst panels of closel y rel at e d no n -p athog enic or g an i s ms.  I nPha se II , wewil l expan d the numb erof  Category Ao rg anisms and  im prove throug hpu t by m ul tip l exing . I n add ition, commer cial prot ot y pe MGB Eclipse ( T M)  pro be assays will be de v eloped for eac h of t he s e
 of_known target_samples. The specificity of_the probes_will_be evaluated_against_panels of closely_related non-pathogenic organisms._In Phase II, we_will expand the_number_of Category A organisms and improve throughput by multiplexing. In addition, commercial prototype MGB_Eclipse(TM)_probe assays_will_be_developed for each of these